HEADER TRANSFERASE 04-NOV-04 1WBN TITLE FRAGMENT BASED P38 INHIBITORS COMPND MOL_ID: 1; COMPND 2 MOLECULE: MITOGEN-ACTIVATED PROTEIN KINASE 14; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: MITOGEN-ACTIVATED PROTEIN KINASE P38ALPHA, MAP COMPND 5 KINASE P38ALPHA, CYTOKINE SUPPRESSIVE ANTI-INFLAMMATORY COMPND 6 DRUG BINDING PROTEIN, CSAID BINDING PROTEIN, CSBP, COMPND 7 MAX-INTERACTING PROTEIN 2, MAP KINASE MXI2, SAPK2A; COMPND 8 EC: 2.7.1.37; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3) KEYWDS P38 MAP KINASE, INHIBITOR STRUCTURE, ALTERNATIVE SPLICING, KEYWDS 2 ATP-BINDING, NUCLEAR PROTEIN, PHOSPHORYLATION, KEYWDS 3 SERINE/THREONINE PROTEIN KINASE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR A.CLEASBY,L.A.DEVINE,A.L.GILL,H.JHOTI REVDAT 2 24-FEB-09 1WBN 1 VERSN REVDAT 1 03-NOV-05 1WBN 0 JRNL AUTH A.L.GILL,M.FREDERICKSON,A.CLEASBY,S.J.WOODHEAD, JRNL AUTH 2 M.G.CARR,A.J.WOODHEAD,M.T.WALKER,M.S.CONGREVE, JRNL AUTH 3 L.A.DEVINE,D.TISI,M.O'REILLY,L.C.SEAVERS,D.J.DAVIS, JRNL AUTH 4 J.CURRY,R.ANTHONY,A.PADOVA,C.W.MURRAY,R.A.CARR, JRNL AUTH 5 H.JHOTI JRNL TITL IDENTIFICATION OF NOVEL P38ALPHA MAP KINASE JRNL TITL 2 INHIBITORS USING FRAGMENT-BASED LEAD GENERATION. JRNL REF J.MED.CHEM. V. 48 414 2005 JRNL REFN ISSN 0022-2623 JRNL PMID 15658855 JRNL DOI 10.1021/JM049575N REMARK 2 REMARK 2 RESOLUTION. 2.4 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 43.316 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.0 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 94.8 REMARK 3 NUMBER OF REFLECTIONS : 19221 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.1808 REMARK 3 FREE R VALUE : 0.2438 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.9 REMARK 3 FREE R VALUE TEST SET COUNT : 994 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2834 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 28 REMARK 3 SOLVENT ATOMS : 552 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.133 REMARK 3 B22 (A**2) : 0.642 REMARK 3 B33 (A**2) : -0.509 REMARK 3 B12 (A**2) : 0.000 REMARK 3 B13 (A**2) : 0.000 REMARK 3 B23 (A**2) : 0.000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005089 REMARK 3 BOND ANGLES (DEGREES) : 0.84608 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : 0.362674 REMARK 3 BSOL : 38.9062 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : ION.PARAM REMARK 3 PARAMETER FILE 4 : LIGANDS.PAR REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : ION.TOP REMARK 3 TOPOLOGY FILE 4 : LIGANDS.TOP REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1WBN COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 04-NOV-04. REMARK 100 THE PDBE ID CODE IS EBI-21532. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SRS REMARK 200 BEAMLINE : PX14.1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : CCP4 (SCALA) REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19222 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.400 REMARK 200 RESOLUTION RANGE LOW (A) : 43.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.2 REMARK 200 DATA REDUNDANCY : 3.400 REMARK 200 R MERGE (I) : 0.08000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 6.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 56 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA):NULL REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 23.07050 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 62.86450 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 43.00050 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 62.86450 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 23.07050 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 43.00050 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 GENERATING THE BIOMOLECULE REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 FUNCTION: RESPONDS TO ACTIVATION BY ENVIRONMENTAL STRESS, PRO- REMARK 400 INFLAMMATORY CYTOKINES AND LIPOPOLYSACCHARIDE (LPS) BY REMARK 400 PHOSPHORYLATING A NUMBER OF TRANSCRIPTION FACTORS, SUCH AS ELK1 REMARK 400 AND ATF2 AND SEVERAL DOWNSTREAM KINASES, SUCH AS MAPKAPK2 AND REMARK 400 MAPKAPK5. PLAYS A CRITICAL ROLE IN THE PRODUCTION OF SOME REMARK 400 CYTOKINES, FOR EXAMPLE IL-6. ISOFORM MXI2 ACTIVATION IS REMARK 400 STIMULATED BY MITOGENS AND OXIDATIVE STRESS AND ONLY POORLY REMARK 400 PHOSPHORYLATES ELK1 AND ATF2. REMARK 400 CATALYTIC ACTIVITY: ATP + A PROTEIN = ADP + A PHOSPHOPROTEIN. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 SER A 2 REMARK 465 GLN A 3 REMARK 465 GLU A 356 REMARK 465 GLU A 357 REMARK 465 MET A 358 REMARK 465 GLU A 359 REMARK 465 SER A 360 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 355 CA C O CB CG CD OE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2113 - O HOH A 2295 2.16 REMARK 500 O HOH A 2280 - O HOH A 2304 2.08 REMARK 500 O HOH A 2285 - O HOH A 2502 2.15 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 57 74.91 30.87 REMARK 500 ARG A 149 -15.66 78.68 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE L09 A1355 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1A9U RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE REMARK 900 P38/SB203580 REMARK 900 RELATED ID: 1BL6 RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE REMARK 900 P38/SB216995 REMARK 900 RELATED ID: 1BL7 RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE REMARK 900 P38/SB220025 REMARK 900 RELATED ID: 1BMK RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE REMARK 900 P38/SB218655 REMARK 900 RELATED ID: 1DI9 RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 MITOGEN-ACTIVATED REMARK 900 PROTEIN KINASE INCOMPLEX WITH 4-[3- REMARK 900 METHYLSULFANYLANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1IAN RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE INHIBITOR COMPLEX REMARK 900 RELATED ID: 1KV1 RELATED DB: PDB REMARK 900 P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1 REMARK 900 RELATED ID: 1KV2 RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB REMARK 900 796 REMARK 900 RELATED ID: 1M7Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 MAP KINASE IN REMARK 900 COMPLEX WITH ADIHYDROQUINAZOLINONE INHIBITOR REMARK 900 RELATED ID: 1OUK RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH REMARK 900 APYRIDINYLIMIDAZOLE INHIBITOR REMARK 900 RELATED ID: 1OUY RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH REMARK 900 A DIHYDROPYRIDO-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OVE RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH REMARK 900 ADIHYDROQUINOLINONE REMARK 900 RELATED ID: 1OZ1 RELATED DB: PDB REMARK 900 P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH REMARK 900 4-AZAINDOLEINHIBITOR REMARK 900 RELATED ID: 1R39 RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA REMARK 900 RELATED ID: 1R3C RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA C162S MUTANT REMARK 900 RELATED ID: 1W7H RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH REMARK 900 SMALL MOLECULE INHIBITOR REMARK 900 RELATED ID: 1W82 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH REMARK 900 SMALL MOLECULE INHIBITOR REMARK 900 RELATED ID: 1W83 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH REMARK 900 SMALL MOLECULE INHIBITOR REMARK 900 RELATED ID: 1W84 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH REMARK 900 SMALL MOLECULE INHIBITOR REMARK 900 RELATED ID: 1WBO RELATED DB: PDB REMARK 900 FRAGMENT BASED P38 INHIBITORS REMARK 900 RELATED ID: 1WBS RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE REMARK 900 INHIBITORS USING FRAGMENT-BASED LEAD REMARK 900 GENERATION. REMARK 900 RELATED ID: 1WBT RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE REMARK 900 INHIBITORS USING FRAGMENT-BASED LEAD REMARK 900 GENERATION. REMARK 900 RELATED ID: 1WBV RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE REMARK 900 INHIBITORS USING FRAGMENT-BASED LEAD REMARK 900 GENERATION. REMARK 900 RELATED ID: 1WBW RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE REMARK 900 INHIBITORS USING FRAGMENT-BASED LEAD REMARK 900 GENERATION. REMARK 900 RELATED ID: 1WFC RELATED DB: PDB REMARK 900 STRUCTURE OF APO, UNPHOSPHORYLATED, P38 REMARK 900 MITOGEN ACTIVATEDPROTEIN KINASE P38 (P38 MAP REMARK 900 KINASE) THE MAMMALIAN HOMOLOGUEOF THE YEAST REMARK 900 HOG1 PROTEIN REMARK 900 RELATED ID: 1YQJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX REMARK 900 WITH A SELECTIVEPYRIDAZINE INHIBITOR REMARK 900 RELATED ID: 1ZZ2 RELATED DB: PDB REMARK 900 TWO CLASSES OF P38ALPHA MAP KINASE REMARK 900 INHIBITORS HAVING ACOMMON DIPHENYLETHER CORE REMARK 900 BUT EXHIBITING DIVERGENT BINDINGMODES REMARK 900 RELATED ID: 1ZZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE INITIAL MET WAS NOT OBSERVED IN THE SEQUENCING REMARK 999 EXPERIMENT THAT DETERMINED THE SEQUENCE OF THE UNIPROT REMARK 999 ENTRY, BUT THIS INITIAL MET IS PRESUMED TO EXIST AND REMARK 999 IS DESCRIBED IN AN ANNOTATION IN THE UNIPROT ENTRY. DBREF 1WBN A 1 1 PDB 1WBN 1WBN 1 1 DBREF 1WBN A 2 360 UNP Q16539 MK14_HUMAN 1 359 SEQRES 1 A 360 MET SER GLN GLU ARG PRO THR PHE TYR ARG GLN GLU LEU SEQRES 2 A 360 ASN LYS THR ILE TRP GLU VAL PRO GLU ARG TYR GLN ASN SEQRES 3 A 360 LEU SER PRO VAL GLY SER GLY ALA TYR GLY SER VAL CYS SEQRES 4 A 360 ALA ALA PHE ASP THR LYS THR GLY LEU ARG VAL ALA VAL SEQRES 5 A 360 LYS LYS LEU SER ARG PRO PHE GLN SER ILE ILE HIS ALA SEQRES 6 A 360 LYS ARG THR TYR ARG GLU LEU ARG LEU LEU LYS HIS MET SEQRES 7 A 360 LYS HIS GLU ASN VAL ILE GLY LEU LEU ASP VAL PHE THR SEQRES 8 A 360 PRO ALA ARG SER LEU GLU GLU PHE ASN ASP VAL TYR LEU SEQRES 9 A 360 VAL THR HIS LEU MET GLY ALA ASP LEU ASN ASN ILE VAL SEQRES 10 A 360 LYS CYS GLN LYS LEU THR ASP ASP HIS VAL GLN PHE LEU SEQRES 11 A 360 ILE TYR GLN ILE LEU ARG GLY LEU LYS TYR ILE HIS SER SEQRES 12 A 360 ALA ASP ILE ILE HIS ARG ASP LEU LYS PRO SER ASN LEU SEQRES 13 A 360 ALA VAL ASN GLU ASP CYS GLU LEU LYS ILE LEU ASP PHE SEQRES 14 A 360 GLY LEU ALA ARG HIS THR ASP ASP GLU MET THR GLY TYR SEQRES 15 A 360 VAL ALA THR ARG TRP TYR ARG ALA PRO GLU ILE MET LEU SEQRES 16 A 360 ASN TRP MET HIS TYR ASN GLN THR VAL ASP ILE TRP SER SEQRES 17 A 360 VAL GLY CYS ILE MET ALA GLU LEU LEU THR GLY ARG THR SEQRES 18 A 360 LEU PHE PRO GLY THR ASP HIS ILE ASP GLN LEU LYS LEU SEQRES 19 A 360 ILE LEU ARG LEU VAL GLY THR PRO GLY ALA GLU LEU LEU SEQRES 20 A 360 LYS LYS ILE SER SER GLU SER ALA ARG ASN TYR ILE GLN SEQRES 21 A 360 SER LEU THR GLN MET PRO LYS MET ASN PHE ALA ASN VAL SEQRES 22 A 360 PHE ILE GLY ALA ASN PRO LEU ALA VAL ASP LEU LEU GLU SEQRES 23 A 360 LYS MET LEU VAL LEU ASP SER ASP LYS ARG ILE THR ALA SEQRES 24 A 360 ALA GLN ALA LEU ALA HIS ALA TYR PHE ALA GLN TYR HIS SEQRES 25 A 360 ASP PRO ASP ASP GLU PRO VAL ALA ASP PRO TYR ASP GLN SEQRES 26 A 360 SER PHE GLU SER ARG ASP LEU LEU ILE ASP GLU TRP LYS SEQRES 27 A 360 SER LEU THR TYR ASP GLU VAL ILE SER PHE VAL PRO PRO SEQRES 28 A 360 PRO LEU ASP GLN GLU GLU MET GLU SER HET L09 A1355 28 HETNAM L09 N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4- HETNAM 2 L09 CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL} HETNAM 3 L09 UREA HETSYN L09 P38 MAP KINASE INHIBITOR FORMUL 2 L09 C20 H22 CL N5 O2 FORMUL 3 HOH *552(H2 O1) HELIX 1 1 SER A 61 MET A 78 1 18 HELIX 2 2 SER A 95 PHE A 99 5 5 HELIX 3 3 ASP A 112 GLN A 120 1 9 HELIX 4 4 THR A 123 ALA A 144 1 22 HELIX 5 5 LYS A 152 SER A 154 5 3 HELIX 6 6 VAL A 183 TYR A 188 1 6 HELIX 7 7 ALA A 190 LEU A 195 1 6 HELIX 8 8 GLN A 202 GLY A 219 1 18 HELIX 9 9 ASP A 227 GLY A 240 1 14 HELIX 10 10 GLY A 243 LYS A 249 1 7 HELIX 11 11 SER A 252 GLN A 260 1 9 HELIX 12 12 ASN A 269 VAL A 273 5 5 HELIX 13 13 ASN A 278 LEU A 289 1 12 HELIX 14 14 ASP A 292 ARG A 296 5 5 HELIX 15 15 THR A 298 ALA A 304 1 7 HELIX 16 16 HIS A 305 ALA A 309 5 5 HELIX 17 17 GLN A 325 ARG A 330 5 6 HELIX 18 18 LEU A 333 PHE A 348 1 16 SHEET 1 AA 2 PHE A 8 GLU A 12 0 SHEET 2 AA 2 ILE A 17 PRO A 21 -1 O TRP A 18 N GLN A 11 SHEET 1 AB 5 TYR A 24 GLY A 33 0 SHEET 2 AB 5 GLY A 36 ASP A 43 -1 O GLY A 36 N GLY A 33 SHEET 3 AB 5 LEU A 48 LEU A 55 -1 O LEU A 48 N ASP A 43 SHEET 4 AB 5 TYR A 103 HIS A 107 -1 O LEU A 104 N LYS A 53 SHEET 5 AB 5 ASP A 88 PHE A 90 -1 O ASP A 88 N VAL A 105 SHEET 1 AC 2 LEU A 156 VAL A 158 0 SHEET 2 AC 2 LEU A 164 ILE A 166 -1 O LYS A 165 N ALA A 157 SITE 1 AC1 15 ALA A 51 LYS A 53 GLU A 71 LEU A 74 SITE 2 AC1 15 LEU A 75 MET A 78 ILE A 84 THR A 106 SITE 3 AC1 15 MET A 109 ILE A 166 LEU A 167 ASP A 168 SITE 4 AC1 15 HOH A2550 HOH A2551 HOH A2552 CRYST1 46.141 86.001 125.729 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021673 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011628 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007954 0.00000